title: Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
abstract: BACKGROUND
  Streptococcus pneumoniae is a leading cause of hospitalization in HIV-infected adults therefore pneumococcal vaccine is recommended. The ideal antipneumococcal vaccine and effective vaccination regimen remain controversial and needs further evaluation.
  
  
  METHODS
  To assess the efficacy of pneumococcal vaccines alone and combined, a randomized, blinded clinical trial was conducted in Brazil with 331 HIV-patients aged 18-60, with CD4-T cell count ≥ 200 cells/mm(3). Two interventions 60 days apart were done in three schedules: 23-valent pneumococcal polysaccharide vaccine (PPV23)/placebo; 7-valent pneumococcal conjugate vaccine (PCV7)/placebo; and PCV7 plus PPV23. Safety and reactogenicity were evaluated, and immunogenicity was assessed by an IgG enzyme-linked immunosorbent assay to S. pneumoniae serotypes 6B, 9V and 14, performed at baseline, 60 and 180 days after first intervention. Comparison of immunogenicity was based on geometric mean concentration (GMC), percentages of individuals with serotype-specific IgG ≥ 0.35μg/mL and ≥ 1.0 μg/mL and proportion of individuals with ≥ 4-fold increase in specific antibody concentrations for each serotype.
  
  
  RESULTS
  Demographic and HIV conditions were similar, and both vaccines were well tolerated across vaccine groups. Significant increase in IgG-antibodies was observed to all serotypes evaluated. A greater proportion of PCV7 recipients reached and sustained IgG antibody concentrations at least four times as high as those at baseline, for serotypes 6B and 9V. A PPV23 dose after PCV7 did not enhance immunogenicity.
  
  
  CONCLUSIONS
  In this first trial conducted with HIV-infected immunologically stable adults in South America, both PPV23 and PCV7 were safe and immunogenic. Evidence suggesting PCV7 was more immunogenic than PPV23, as it elicited higher and persistent ≥ 4-fold increase of antibodies for 6B and 9V serotypes in a greater proportion of HIV-patients is noteworthy. Despite current recommendation of schedules combining PCV7 and PPV23, there is little evidence to support this practice and we did not observe benefits in this combination.
authors.affiliation: Divisão de Moléstias Infecciosas e Parasitárias, Hospital das Clinicas da Faculdade de Medicina da USP, Brazil. hoyehli@yahoo.com.br
authors.forename: Yeh-Li
authors.initials: YL
authors.lastname: Ho
authors.forename: Angela Pires
authors.initials: AP
authors.lastname: Brandão
authors.forename: Maria Cristina
authors.initials: MC
authors.lastname: de Cunto Brandileone
authors.forename: Marta Heloisa
authors.initials: MH
authors.lastname: Lopes
mesh_terms: D000328:Adult; D001938:Brazil; D005260:Female; D015658:HIV Infections; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D014611:Vaccination; D055815:Young Adult
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines
keywords: Adults; Combination vaccines; HIV; Pneumococcal conjugate vaccines; Pneumococcal polysaccharide vaccine